Lawmakers Parrot Drug Makers’ Arguments For Wider CAR-T Coverage

As the May 17 final coverage decision looms, bipartisan groups of Senate and House lawmakers are taking the side of drug makers that want Medicare to cover expensive CAR-T cancer therapies for more patients and in more settings. The lawmakers ask that CMS let doctors administer chimeric antigen receptor (CAR) T-cells therapy outside of hospitals, pay for off-label indications, avoid disrupting care of patients already receiving CAR-T and avoid excluding coverage of future cell and gene therapy therapies. CMS is...